U.S. pharma big copyright scrapped two experimental weight loss products previous yr—a once-each day tablet, lotiglipron, because of elevated liver enzymes and also a 2 times-day by day pill, danuglipron, on account of strong side effects—but CEO Albert Bourla has said the company is decided to “Participate in and acquire” from the obesity